Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion type Assertion NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_head.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion description "[ This weekly irinotecan/docetaxel regimen has shown an acceptable toxicity profile while encouraging median and 1-year survival in heavily pretreated NSCLC patients. The tendency to better prognosis in patients carrying the variant genotypes 6/7 and 7/7 o]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_provenance.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion evidence source_evidence_literature NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_provenance.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion SIO_000772 14586211 NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_provenance.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion wasDerivedFrom gad-20150221 NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_provenance.
- NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_assertion wasGeneratedBy ECO_0000203 NP82351.RAJuxwWbMSQBR7MO6Qo14o9wAEk87Y_nLIU-5kK01bxc0130_provenance.